Stocks / Stock overview

Tempus AI, Inc. (TEM)

$85.01+3.37%Aft $84.57 (-0.52%)Market cap $15.34B

NasdaqGS · Price as of · Nasdaq Real Time Price

Stock Scorer
C51/100
  • Profitability5/20

    Losing money ($-228.6M over the last four reported quarters), but the top line is growing fast. Revenue over the last four reported quarters was $1.43B, up 47% from $971.7M the year before. Growth this quick earns partial credit; it still has to turn into profit.

  • Insider buying vs selling8/20

    Insiders are sellers only: 81 sells worth $71.0M, no open-market buys, across the last 20 Form 4s. Routine executive selling is common, so this is only a mild negative.

  • Dilution and offeringsn/a

    Share count history unavailable in EDGAR.

See the full breakdown
Analyst consensus
Buy$68.56
  • Analysts18
  • Implied upside-19.4%
  • Target range$35.00 to $100.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
November 3, 2026date estimated
  • EPS expected-$0.08
  • A year ago-$0.11
  • Revenue expected$410.2M +23%
  • Estimate range-$0.17 to $0.00
Consensus of 14 analysts for the quarter ending September 30, 2026. Beat the estimate in all four of the last four quarters. Estimates are what Wall Street expects, not our forecast.
Source: Yahoo Finance earnings calendar
TEM past month+24.1%
TEM closed at $85.01 on Sep 25, up 24.1% since Aug 26.$85.01$53.73Aug 26Sep 25
Close 20-day average 50-day average 200-day average

TEM closed at $85.01 on Sep 25, up 24.1% since Aug 26. Chart read: price above both the 50-day and 200-day moving averages; the 50-day is above the 200-day (uptrend structure); trading at 70% of the 52-week range ($41.55 to $103.25).

Insider buying and selling at Tempus AI, Inc. (TEM)

Source: SEC Form 4 filingsLatest filed

The most recent Form 4 on record for Tempus AI, Inc. (TEM) is September 22, 2026, when Eric P Lefkofsky, CEO and Chairman, sold $19.4M of stock. That sale ran under a pre-arranged 10b5-1 plan, so it was scheduled ahead of time rather than decided that week.

InsiderActionValueDateType
Eric P Lefkofsky · CEO and ChairmanSell$19.4MSeptember 22, 2026Routine
Eric P Lefkofsky · CEO and ChairmanSell$16.1MSeptember 17, 2026Routine
Eric P Lefkofsky · CEO and ChairmanSell$16.3MAugust 25, 2026Routine
Eric P Lefkofsky · CEO and ChairmanSell$6.6MAugust 18, 2026No decision
Eric P Lefkofsky · CEO and ChairmanSell$10.5MJuly 28, 2026Routine
All insider activity

Filed notices to sell

Source: SEC Form 144 noticesLatest filed

A Form 144 is filed beforean insider sells restricted stock. The Form 4 reporting the completed trade isn't due until two business days after the sale, so these land first. They are intentions, not transactions.

InsiderValueFiledStatusType
Schoenherr Thomas Edward · Officer$845,509September 25, 2026Not yet reportedRoutine
Polovin Andrew · Officer$206,481September 17, 2026ExecutedRoutine
Bartolucci Ryan M · Officer$651,491September 17, 2026ExecutedRoutine
Fukushima Ryan · Officer$48,195September 16, 2026Not yet reportedRoutine
Doudna Jennifer A · Director$42,622September 1, 2026Not yet reportedRoutine
All filed notices

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
144September 25, 2026View on EDGAR
4September 24, 2026View on EDGAR
144September 22, 2026View on EDGAR
4September 18, 2026View on EDGAR
4September 18, 2026View on EDGAR
4September 18, 2026View on EDGAR
4September 18, 2026View on EDGAR
144September 17, 2026View on EDGAR
All SEC filings

Tempus AI news

Tempus AI (TEM) rose 47% on a Merck and Moderna trial. Two analysts upgraded it after the run.
News

Tempus AI (TEM) rose 47% on a Merck and Moderna trial. Two analysts upgraded it after the run.

Cantor Fitzgerald initiated Tempus AI (TEM) at overweight with an $80 target, two days after Piper Sandler upgraded it. The 47% run both calls follow came from a Merck and Moderna Phase 3 readout, and the insider sales that made headlines were mostly automatic tax withholding.

Sep 3, 2026
Tempus AI (TEM) just turned its first profit. Its stock is still half off its high.
News

Tempus AI (TEM) just turned its first profit. Its stock is still half off its high.

A deep dive on Tempus AI (TEM): what the cancer-data company does, its first quarterly profit, who controls the stock, the short-seller report against it, and why Wall Street can't agree on the price.

Aug 16, 2026

Frequently asked questions

When does TEM report earnings?

Tempus AI, Inc. (TEM) is scheduled to report quarterly results on November 3, 2026 (estimated). The 14-analyst consensus is -$0.08 per share on revenue of $410.2M for the quarter ending September 30, 2026, against -$0.11 and $334.2M a year earlier. It has beaten the consensus EPS estimate in all four of the last four quarters. The date is an estimate from past reporting patterns and can move until the company confirms it.

What do analysts expect for TEM?

18 analysts cover Tempus AI, Inc. (TEM). The consensus rating is Buy. The average price target is $68.56, in a range of $35.00 to $100.00.

Are insiders buying or selling TEM?

We track Form 4 filings for Tempus AI, Inc. (TEM). The activity listed on this page shows 5 qualifying sales. Each row is labelled Routine when the filer declared a pre-arranged 10b5-1 plan, Tax withholding when shares were sold automatically to cover the tax on a vest, or Own call when neither applies.

Where can I see TEM SEC filings?

Recent filings are listed on this page, newest first. The latest is a 144 filed September 25, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.